Peptide-based angiogenesis inhibitors and methods of use thereof
AssigneeThe Scripps Research Institute
InventorsDavid A. Cheresh, John Hood, Martin A. Schwartz, William B. Kiosses
Life of this patent
Estimating the term…
Abstract
Angiogenesis inhibitors and methods of use thereof are disclosed. The inhibitors are substantially pure oligopeptides consisting essentially of 7–20 amino acid residues and comprising a proline-rich sequence of five amino acid residues PPXPP, SEQ ID NO: 1, wherein X is an amino acid residue selected from the group consisting of alanine, glycine, serine, threonine, valine, leucine and methionine. In a preferred embodiment, the proline-rich polypeptide is covalently bound to a transport molecule such as a Tat-derived transport polypeptide.
Claims12
A oligopeptide including a proline-rich segment having a total of 7 to 20 amino acid residues and including at least one amino acid sequence PPXPP (SEQ ID NO:
- 1), covalently bound to a transport molecule segment;
- wherein X is an amino acid residue selected from the group consisting of A, G, S, T, L and M;
- the oligopeptide having angiogenesis inhibiting activity.
A oligopeptide including a proline-rich segment and at least one amino acid sequence PPXPP (SEQ ID NO:
- 1), covalently bound to a transport molecule segment;
- wherein X is an amino acid residue selected from the group consisting of A, G, S, T, L and M;
- the oligopeptide having angiogenesis inhibiting activity and wherein the proline-rich segment has a total of 8 amino acid residues.
Dependencies are inferred from the claim text.